Cellcentric

CellCentric develops inobrodib, an oral small molecule that inhibits the twin proteins p300 and CBP, which act as transcription co-activators of cancer-related genes. The drug is in clinical trials, mainly for multiple myeloma, and is also being evaluated with other standard-of-care therapies.

The website describes separate sections for patients and physicians and states that the company aims to develop inobrodib for people with multiple myeloma and other cancers. One planned use is an oral combination with pomalidomide and dexamethasone for community settings. The website does not describe a commercial revenue model.

Registry data lists Esslingen, Germany as the headquarters and 2021 as the founding year. The team page lists a CEO, a senior leadership group and a board that includes investor directors. The careers page lists eight open roles in clinical, quality, medical affairs, IT and administrative functions, six of them labelled US or UK.

Product: Inobrodib, an oral small molecule p300/CBP inhibitor in clinical development for multiple myeloma and other cancers.